Cabaletta Bio, Inc. (CABA)
2.00
+0.11
(+5.82%)
USD |
NASDAQ |
Oct 02, 16:00
2.02
+0.02
(+1.00%)
Pre-Market: 08:59
Cabaletta Bio Enterprise Value : 136.06M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 136.06M |
| October 01, 2026 | 117.62M |
| September 30, 2026 | 122.65M |
| September 29, 2026 | 132.71M |
| September 28, 2026 | 136.06M |
| September 25, 2026 | 147.81M |
| September 24, 2026 | 162.06M |
| September 23, 2026 | 172.96M |
| September 22, 2026 | 219.93M |
| September 21, 2026 | 213.22M |
| September 18, 2026 | 228.31M |
| September 17, 2026 | 233.35M |
| September 16, 2026 | 218.25M |
| September 15, 2026 | 235.86M |
| September 14, 2026 | 288.70M |
| September 11, 2026 | 258.51M |
| September 10, 2026 | 260.18M |
| September 09, 2026 | 288.70M |
| September 08, 2026 | 349.08M |
| September 04, 2026 | 382.62M |
| September 03, 2026 | 384.30M |
| September 02, 2026 | 399.40M |
| September 01, 2026 | 354.11M |
| August 31, 2026 | 322.24M |
| August 28, 2026 | 323.92M |
| Date | Value |
|---|---|
| August 27, 2026 | 367.53M |
| August 26, 2026 | 345.72M |
| August 25, 2026 | 340.69M |
| August 24, 2026 | 320.56M |
| August 21, 2026 | 325.60M |
| August 20, 2026 | 335.66M |
| August 19, 2026 | 320.56M |
| August 18, 2026 | 288.70M |
| August 17, 2026 | 285.34M |
| August 14, 2026 | 261.86M |
| August 13, 2026 | 255.15M |
| August 12, 2026 | 278.63M |
| August 11, 2026 | 268.57M |
| August 10, 2026 | 270.25M |
| August 07, 2026 | 268.57M |
| August 06, 2026 | 263.54M |
| August 05, 2026 | 255.15M |
| August 04, 2026 | 265.21M |
| August 03, 2026 | 251.80M |
| July 31, 2026 | 250.12M |
| July 30, 2026 | 256.83M |
| July 29, 2026 | 240.06M |
| July 28, 2026 | 258.51M |
| July 27, 2026 | 256.83M |
| July 24, 2026 | 251.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 620.93M |
| Amgen, Inc. | 261.20B |
| BioCryst Pharmaceuticals, Inc. | 2.569B |
| Imunon, Inc. | 6.953M |
| Curis, Inc. | -3.007M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.02M |
| Total Expenses (Quarterly) | 51.02M |
| EPS Diluted (Quarterly) | -0.3375 |
| Earnings Yield | -79.09% |
| Normalized Earnings Yield | -79.10 |